touchPODCAST

By touchpodcast

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.

Educating physicians on a fully global... more

· Science

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about touchPODCAST:

How many episodes does touchPODCAST have?

The podcast currently has 542 episodes available.

touchPODCAST episodes:

November 14, 2024touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4
touchMDT for touchONCOLOGY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
www.touchONCOLOGY.com
...more
14min
November 14, 2024touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3
touchMDT for touchONCOLOGY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
www.touchONCOLOGY.com
...more
17min
November 14, 2024touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4
touchMDT for touchRESPIRATORY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
www.touchRESPIRATORY.com
...more
14min
November 14, 2024touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3
touchMDT for touchRESPIRATORY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
www.touchRESPIRATORY.com
...more
17min
November 13, 2024 touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchRESPIRATORY
What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.
The multidisciplinary team
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
...more
16min
November 13, 2024 touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchRESPIRATORY
What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.
The multidisciplinary team
Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
...more
14min
November 13, 2024 touchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchRESPIRATORY
What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.
The multidisciplinary team:
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
...more
15min
November 13, 2024 touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchONCOLOGY
What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.
The multidisciplinary team
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
...more
16min
November 13, 2024 touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchONCOLOGY
What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.
The multidisciplinary team
Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
...more
14min
November 13, 2024 touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchONCOLOGY
What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.
The multidisciplinary team:
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
...more
15min

FAQs about touchPODCAST:

How many episodes does touchPODCAST have?

The podcast currently has 542 episodes available.